Cytochrome P-450 3A4 - The most important arena for drug interactions in the body;Cytokrom P-450 3A4 - Kroppens viktigste arena for legemiddelinteraksjoner

Tidsskrift for den Norske Laegeforening

Volumn 128, Issue 24, 2008, Pages 2832-2835

  Spigset, Olav ^a,b   Molden, Espen ^c,d  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d DIAKONHJEMMET HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58149231045     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Paine MF, Hart HL, Ludington SS et al. The human intestinal cytochrome P450 «pie». Drug Metab Dispos 2006; 34: 880-6.
2. Lin YS, Dowling ALS, Quigley SD et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62: 162-72.
3. Westlind-Johnsson A, Malmebo S, Johansson A et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 2003; 31: 755-61.
4. Molden E, Åsberg A. Metabolismeinteraksjoner med statiner. Tidsskr Nor Lægeforen 2001; 121: 189-93.
5. Omar MA, Wilson JP. FDA adverse event repors on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36: 288-95.
6. Backmann JT, Olkkola KT, Aranko K et al. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994; 37; 221-5.
7. Ahonen J, Olkkola KT, Salmenperä M et al. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Anesthesiology 1996; 85: 1246-52.
8. De Watcher E, Malfroot A, De Schutter I et al. Inhaled buspirone induced Cushing's syndrome due to drug inhibition of cytochrome P450. J Cyst Fibros 2003; 2: 72-5.
9. Parmaar JS, Howell T, Kelly J. Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax 2002; 57: 749-50.
10. Bailey DG, Bend JR, Arnold JM et al. Erythromycin - felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther 1996; 60: 25-33.
11. Molden E, Spigset O. Frukt og bær - interaksjoner med legemidler. Tidsskr Nor Lægeforen 2007; 24: 3218-20.
12. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 2006; 78: 2131-45.
13. Jaruratanasirikul S, Sriwiriyajan S. Pharmacokinetics of rifampicin administered alone and with indinavir. J Antimicrob Chemother 1999; 44 (suppl A): 58.
14. Justesen US, Andersen ÅB, Klitgaard NA et al. Pharmacokinetic interactions between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clin Infect Dis 2004; 38: 426-9.
15. Kantola T, Kivistö KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177-82.
16. Schvarcz R, Rudbeck G, Söderdahl G et al. Interactions between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus. Transplantation 2000; 69: 2194-5.
17. Hardy G, Stanke-Labesque F, Contamin C et al. Protease inhibitors and diltiazem increase tacrolimus blood concentration in a patient with renal transplantation. Eur J Clin Pharmacol 2004; 60: 603-5.
18. Molden E. P-glykoprotein - en pumpe av betydning for legemiddelrespons. Tidsskr Nor Lægeforen 2004; 124: 2921-3.
19. Spigset O. Legemiddelinteraksjoner. I: Tørisen HM, red. Felleskatalogen. Oslo: Felleskatalogen AS, 2008: 1e-109e. www.felleskatalogen. no/ (21.10.2008).
20. Spigset O. Interaksjoner. I: Vilberg A, red. Norsk legemiddelhå ndbok for helsepersonell 2007. Oslo: Foreningen for utgivelse av Norsk legemiddelhåndbok, 2007: 1315-430. www.legemiddelhandboka.no/ (21.10.2008).
21. Baxter K, red. Stockley's drug interactions. 8. utg. London: The Pharmaceutical Press, 2008.